...
itci-img

Intracellular Th, Common Stock

ITCI

NSQ

$85.11

+$2.08

(2.51%)

1D
Industry: Pharmaceuticals Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$8.80B
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
448.74K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.97
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$62.78 L
$93.45 H
$85.11

About Intracellular Th, Common Stock

Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York. more

Industry: PharmaceuticalsSector: Health Care

Returns

Time FrameITCISectorS&P500
1-Week Return0.18%-3.72%-0.05%
1-Month Return3.2%-1.85%2.75%
3-Month Return13.09%-11.4%7.4%
6-Month Return23.58%-4.41%10.47%
1-Year Return30.42%4.13%27.57%
3-Year Return130.21%0.3%29.56%
5-Year Return559.26%36.62%89.3%
10-Year Return440.38%106.81%206.09%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue60.61K22.53M81.71M249.13M464.37M[{"date":"2019-12-31","value":0.01,"profit":true},{"date":"2020-12-31","value":4.85,"profit":true},{"date":"2021-12-31","value":17.6,"profit":true},{"date":"2022-12-31","value":53.65,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Cost of Revenue89.12M1.90M8.03M20.44M33.74M[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":2.13,"profit":true},{"date":"2021-12-31","value":9.01,"profit":true},{"date":"2022-12-31","value":22.94,"profit":true},{"date":"2023-12-31","value":37.86,"profit":true}]
Gross Profit60.61K20.64M73.67M228.69M430.63M[{"date":"2019-12-31","value":0.01,"profit":true},{"date":"2020-12-31","value":4.79,"profit":true},{"date":"2021-12-31","value":17.11,"profit":true},{"date":"2022-12-31","value":53.11,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Margin100.00%91.59%90.17%91.79%92.73%[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":91.59,"profit":true},{"date":"2021-12-31","value":90.17,"profit":true},{"date":"2022-12-31","value":91.79,"profit":true},{"date":"2023-12-31","value":92.73,"profit":true}]
Operating Expenses154.07M251.86M359.36M492.31M590.01M[{"date":"2019-12-31","value":26.11,"profit":true},{"date":"2020-12-31","value":42.69,"profit":true},{"date":"2021-12-31","value":60.91,"profit":true},{"date":"2022-12-31","value":83.44,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Income(154.01M)(231.23M)(285.69M)(263.63M)(159.38M)[{"date":"2019-12-31","value":-15401185000,"profit":false},{"date":"2020-12-31","value":-23122763100,"profit":false},{"date":"2021-12-31","value":-28568812500,"profit":false},{"date":"2022-12-31","value":-26362600000,"profit":false},{"date":"2023-12-31","value":-15938100000,"profit":false}]
Total Non-Operating Income/Expense12.58M8.47M3.14M14.75M40.69M[{"date":"2019-12-31","value":30.93,"profit":true},{"date":"2020-12-31","value":20.82,"profit":true},{"date":"2021-12-31","value":7.71,"profit":true},{"date":"2022-12-31","value":36.26,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Pre-Tax Income(147.72M)(226.99M)(284.12M)(256.25M)(139.04M)[{"date":"2019-12-31","value":-14772057800,"profit":false},{"date":"2020-12-31","value":-22699215000,"profit":false},{"date":"2021-12-31","value":-28412003500,"profit":false},{"date":"2022-12-31","value":-25625000000,"profit":false},{"date":"2023-12-31","value":-13903800000,"profit":false}]
Income Taxes1.60K13.51K5.63K6.00K636.00K[{"date":"2019-12-31","value":0.25,"profit":true},{"date":"2020-12-31","value":2.12,"profit":true},{"date":"2021-12-31","value":0.89,"profit":true},{"date":"2022-12-31","value":0.94,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Income After Taxes(147.72M)(227.01M)(284.13M)(256.26M)(139.67M)[{"date":"2019-12-31","value":-14772217800,"profit":false},{"date":"2020-12-31","value":-22700566300,"profit":false},{"date":"2021-12-31","value":-28412566600,"profit":false},{"date":"2022-12-31","value":-25625600000,"profit":false},{"date":"2023-12-31","value":-13967400000,"profit":false}]
Income From Continuous Operations(147.72M)(227.01M)(284.13M)(256.26M)(139.67M)[{"date":"2019-12-31","value":-14772217800,"profit":false},{"date":"2020-12-31","value":-22700566300,"profit":false},{"date":"2021-12-31","value":-28412566600,"profit":false},{"date":"2022-12-31","value":-25625600000,"profit":false},{"date":"2023-12-31","value":-13967400000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(147.72M)(227.01M)(284.13M)(256.26M)(139.67M)[{"date":"2019-12-31","value":-14772217800,"profit":false},{"date":"2020-12-31","value":-22700566300,"profit":false},{"date":"2021-12-31","value":-28412566600,"profit":false},{"date":"2022-12-31","value":-25625600000,"profit":false},{"date":"2023-12-31","value":-13967400000,"profit":false}]
EPS (Diluted)(2.68)(3.24)(3.50)(2.72)(1.46)[{"date":"2019-12-31","value":-268,"profit":false},{"date":"2020-12-31","value":-324,"profit":false},{"date":"2021-12-31","value":-350,"profit":false},{"date":"2022-12-31","value":-272,"profit":false},{"date":"2023-12-31","value":-146,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

ITCI
Cash Ratio 6.06
Current Ratio 7.66
Quick Ratio 7.51

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

ITCI
ROA (LTM) -7.45%
ROE (LTM) -9.90%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

ITCI
Debt Ratio Lower is generally better. Negative is bad. 0.14
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.86

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

ITCI
Trailing PE NM
Forward PE 208.33
P/S (TTM) 14.34
P/B 7.69
Price/FCF NM
EV/R 12.75
EV/Ebitda NM
PEG NM

FAQs

What is Intracellular Th share price today?

Intracellular Th (ITCI) share price today is $85.11

Can Indians buy Intracellular Th shares?

Yes, Indians can buy shares of Intracellular Th (ITCI) on Vested. To buy Intracellular Th from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in ITCI stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Intracellular Th be purchased?

Yes, you can purchase fractional shares of Intracellular Th (ITCI) via the Vested app. You can start investing in Intracellular Th (ITCI) with a minimum investment of $1.

How to invest in Intracellular Th shares from India?

You can invest in shares of Intracellular Th (ITCI) via Vested in three simple steps:

  • Click on Sign Up or Invest in ITCI stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Intracellular Th shares
What is Intracellular Th 52-week high and low stock price?

The 52-week high price of Intracellular Th (ITCI) is $93.45. The 52-week low price of Intracellular Th (ITCI) is $62.78.

What is Intracellular Th price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Intracellular Th (ITCI) is

What is Intracellular Th price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Intracellular Th (ITCI) is 7.69

What is Intracellular Th dividend yield?

The dividend yield of Intracellular Th (ITCI) is 0.00%

What is the Market Cap of Intracellular Th?

The market capitalization of Intracellular Th (ITCI) is $8.80B

What is Intracellular Th’s stock symbol?

The stock symbol (or ticker) of Intracellular Th is ITCI

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top